Advertisement
NTRB vs SYRE
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NTRB is a Hold and SYRE is a StrongBuy.
NTRB's RSI Oscillator leaves overbought zone
The 10-day RSI Indicator for NTRB moved out of overbought territory on September 25, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 22 instances where the indicator moved out of the overbought zone. In 21 of the 22 cases the stock moved lower in the days that followed. This puts the odds of a move down at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 01, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on NTRB as a result. In 87 of 98 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 89%.
The Moving Average Convergence Divergence Histogram (MACD) for NTRB turned negative on September 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In 38 of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at 84%.
NTRB moved below its 50-day moving average on October 22, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NTRB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
NTRB broke above its upper Bollinger Band on September 24, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 12 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The 50-day moving average for NTRB moved above the 200-day moving average on September 17, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Following a +3.12% 3-day Advance, the price is estimated to grow further. Considering data from situations where NTRB advanced for three days, in 197 of 245 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
The Aroon Indicator entered an Uptrend today. In 77 of 113 cases where NTRB Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 68%.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. NTRB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 60 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (13.261) is normal, around the industry mean (2.973). P/E Ratio (-11.857) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (52.632) is also within normal values, averaging (438.009).
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NTRB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
SYRE in upward trend: price rose above 50-day moving average on October 21, 2026
SYRE moved above its 50-day moving average on October 21, 2026 date and that indicates a change from a downward trend to an upward trend. In 42 of 45 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on SYRE as a result. In 68 of 78 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 87%.
The Moving Average Convergence Divergence (MACD) for SYRE just turned positive on October 20, 2026. Looking at past instances where SYRE's MACD turned positive, the stock continued to rise in 37 of 42 cases over the following month. The odds of a continued upward trend are 88%.
Following a +9.71% 3-day Advance, the price is estimated to grow further. Considering data from situations where SYRE advanced for three days, in 259 of 299 cases, the price rose further within the following month. The odds of a continued upward trend are 87%.
SYRE may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SYRE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
The Aroon Indicator for SYRE entered a downward trend on October 01, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 4 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.527) is normal, around the industry mean (2.973). P/E Ratio (-48.104) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (526.316) is also within normal values, averaging (438.009).
The Tickeron PE Growth Rating for this company is 34 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. SYRE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SYRE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
NTRB | SYRE | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 93 | 25 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 60 Fair valued | 4 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 99 | 96 | |
PRICE GROWTH RATING 1..100 | 37 | 35 | |
P/E GROWTH RATING 1..100 | 100 | 34 | |
SEASONALITY SCORE 1..100 | n/a | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
SYRE's Valuation (4) in the Pharmaceuticals Major industry is somewhat better than the same rating for NTRB (60) in the null industry. This means that SYRE’s stock grew somewhat faster than NTRB’s over the last 12 months.
SYRE's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as NTRB (100) in the null industry. This means that SYRE’s stock grew similarly to NTRB’s over the last 12 months.
SYRE's SMR Rating (96) in the Pharmaceuticals Major industry is in the same range as NTRB (99) in the null industry. This means that SYRE’s stock grew similarly to NTRB’s over the last 12 months.
SYRE's Price Growth Rating (35) in the Pharmaceuticals Major industry is in the same range as NTRB (37) in the null industry. This means that SYRE’s stock grew similarly to NTRB’s over the last 12 months.
SYRE's P/E Growth Rating (34) in the Pharmaceuticals Major industry is significantly better than the same rating for NTRB (100) in the null industry. This means that SYRE’s stock grew significantly faster than NTRB’s over the last 12 months.
| NTRB | SYRE | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 90% | N/A |
| Stochastic ODDS (%) | 1 day ago 76% | 1 day ago 88% |
| Momentum ODDS (%) | 1 day ago 89% | 1 day ago 87% |
| MACD ODDS (%) | 1 day ago 84% | 1 day ago 88% |
| TrendWeek ODDS (%) | 1 day ago 88% | 1 day ago 86% |
| TrendMonth ODDS (%) | 1 day ago 87% | 1 day ago 88% |
| Advances ODDS (%) | 24 days ago 80% | 2 days ago 87% |
| Declines ODDS (%) | 3 days ago 87% | 9 days ago 87% |
| BollingerBands ODDS (%) | 1 day ago 89% | 1 day ago 86% |
| Aroon ODDS (%) | 1 day ago 68% | 1 day ago 90% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
NTRB’s FA Score shows that 0 FA rating(s) are green while SYRE’s FA Score has 1 green FA rating(s).
- NTRB’s FA Score: 0 green, 5 red.
- SYRE’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
NTRB’s TA Score shows that 5 TA indicator(s) are bullish while SYRE’s TA Score has 5 bullish TA indicator(s).
- NTRB’s TA Score: 5 bullish, 5 bearish.
- SYRE’s TA Score: 5 bullish, 3 bearish.
Price Growth
NTRB (@Biotechnology) experienced а -2.85% price change this week, while SYRE (@Biotechnology) price change was +15.27% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -1.10%. For the same industry, the average monthly price growth was -18.18%, and the average quarterly price growth was -15.20%.
Reported Earning Dates
NTRB is expected to report earnings on Dec 09, 2026.
SYRE is expected to report earnings on Nov 03, 2026.
Industries' Descriptions
@Biotechnology (-1.10% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
NTRB and
Correlation & Price change
A.I.dvisor tells us that NTRB and VRAX have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that NTRB and VRAX's prices will move in lockstep.
| Ticker / NAME | Correlation To NTRB | 1D Price Change % | ||
|---|---|---|---|---|
| NTRB | 100% | -5.37% | ||
| VRAX - NTRB | 31% Poorly correlated | -8.21% | ||
| DWTX - NTRB | 28% Poorly correlated | -4.27% | ||
| SYRE - NTRB | 27% Poorly correlated | -0.67% | ||
| JSPR - NTRB | 27% Poorly correlated | -1.73% | ||
| HYPD - NTRB | 27% Poorly correlated | -5.81% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| QQQD | 12.05 | 0.40 | +3.39% |
| Direxion Daily Concentrated Qs Bear 1X Shares | |||
| MIY | 11.80 | 0.07 | +0.60% |
| Blackrock Muniyield Michigan Quality Fund | |||
| CARY | 20.31 | 0.07 | +0.37% |
| Angel Oak Income ETF (CARY) | |||
| ZSB | 20.59 | N/A | N/A |
| USCF Sustainable Battery Metals Strategy Fund (ZSB) | |||
| GSJY | 54.21 | -0.66 | -1.20% |
| Goldman Sachs ActiveBeta Japan Equity ETF (GSJY) | |||